Brainstorm Cell Therapeutics (BCLI) News Today → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free BCLI Stock Alerts $0.38 -0.02 (-5.00%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnfinanznachrichten.de - April 17 at 7:54 AMBrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officermsn.com - April 17 at 7:54 AMBrainstorm Cell Therapeutics (BCLI) Price Target Increased by 150.00% to 2.55msn.com - April 17 at 7:54 AMBrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chiefmarketwatch.com - April 17 at 2:01 AMBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rulefinanznachrichten.de - April 11 at 12:32 PMBCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…finance.yahoo.com - April 11 at 12:32 PMBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Ruleprnewswire.com - April 11 at 6:00 AMBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSfinance.yahoo.com - April 10 at 6:29 AMBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSprnewswire.com - April 10 at 6:00 AMBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSfinance.yahoo.com - April 9 at 7:47 AMBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSprnewswire.com - April 9 at 6:00 AMBrainStorm Cell Therapeutics to Provide Update on NurOwn Programprnewswire.com - April 8 at 6:00 AMBrainstorm Cell: Q4 Earnings Insightsbenzinga.com - April 1 at 12:14 PMBrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Updateprnewswire.com - April 1 at 8:05 AMWhy Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionmsn.com - March 25 at 6:29 PMBCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…finance.yahoo.com - March 6 at 4:40 PMBrainStorm details Phase 3b trial for ALS treatment NurOwninvesting.com - February 29 at 7:27 PMBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conferencefinance.yahoo.com - February 27 at 7:50 AMBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conferenceprnewswire.com - February 27 at 6:30 AMBCLI Mar 2024 1.500 callfinance.yahoo.com - February 25 at 5:51 PMBrainStorm Cell Therapeutics Shares Rise 7.2% on NurOwn Study Request to FDAmarketwatch.com - February 23 at 6:43 PMBrainStorm submits SPA request to FDA for Phase 3 study designmsn.com - February 23 at 1:43 PMBrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALSprnewswire.com - February 23 at 6:00 AMBrainstorm Cell Therapeutics Inc.wsj.com - February 16 at 10:19 AMBrainstorm Cell Therapeutics Inc (BCLI)uk.investing.com - February 13 at 9:59 AMBrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forumfinance.yahoo.com - February 13 at 9:59 AMBrainstorm Cell Therapeutics Inc. (BCLI)finance.yahoo.com - February 1 at 2:48 PMBCLI Brainstorm Cell Therapeutics Inc.seekingalpha.com - January 14 at 3:49 PMBCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before ...businesswire.com - January 1 at 7:41 AMBrainstorm Cell Therapeutics Shares Rise 11% on Patent Approvalsmarketwatch.com - December 26 at 3:45 PMBrainStorm Cell Therapeutics spikes on patent winsmsn.com - December 26 at 10:45 AMBrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatmentsfinance.yahoo.com - December 26 at 10:45 AMINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadlinebarrons.com - December 22 at 9:05 AMBrainStorm Cell Therapeutics Inc.: BrainStorm Issues 2023 Letter to Shareholdersfinanznachrichten.de - December 20 at 1:41 PMBrainStorm Issues 2023 Letter to Shareholdersfinance.yahoo.com - December 20 at 1:41 PMBCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuitmorningstar.com - December 17 at 7:48 PMROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLImarkets.businessinsider.com - December 16 at 3:07 PMBCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwnfinance.yahoo.com - December 8 at 1:16 PMWhy BrainStorm Cell Therapeutics Shares Are Fallingmsn.com - December 7 at 7:08 PMBrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALSfinance.yahoo.com - December 7 at 9:06 AMBrainstorm Cell Therapeutics Inc BCLImorningstar.com - November 28 at 6:16 PMINVESTOR ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BCLIbarrons.com - November 26 at 12:06 AMSHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline -- BCLIbarrons.com - November 23 at 11:55 PMBrainstorm Cell Therapeutics Inc. Class Action Reminder: Contact Robbins LLP for Information About the BCLI Class Actionbenzinga.com - November 21 at 9:10 PMBrainstorm Cell Therapeutics (NASDAQ:BCLI) to Meet with FDA for New Treatment Plansmsn.com - November 21 at 8:50 AMBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!businesswire.com - November 20 at 3:06 PMSHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BCLIbarrons.com - November 20 at 12:12 PMBrainStorm Cell Therapeutics: FDA Grants In-person Meeting To Discuss Best Path Forward For NurOwnmarkets.businessinsider.com - November 20 at 12:12 PMBrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALSfinance.yahoo.com - November 20 at 12:12 PMBrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposiafinance.yahoo.com - November 17 at 7:10 AM Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago. That's why we have released our Free Precious Metals Investment Guide. BCLI Media Mentions By Week BCLI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCLI News Sentiment▼0.000.42▲Average Medical News Sentiment BCLI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCLI Articles This Week▼02▲BCLI Articles Average Week Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CYTH News Today TARA News Today INAB News Today ACHL News Today OKYO News Today SABS News Today INKT News Today NKGN News Today SRZN News Today WINT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCLI) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.